Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Bull: Innovation in Medical Devices and sustained recovery in routine Diagnostics outpace expectations, yielding significant operating leverage.
Libre Market Share Loss: Next-gen competitive continuous glucose monitors or GLP-1 drug advancements severely erode FreeStyle Libre adoption, cratering high-margin medical device growth.
Abbott Laboratories is a diversified, mature global healthcare leader characterized by stable free cash flows and a reliable dividend profile (67% payout ratio). Following a volatile pandemic-era revenue trajectory, the company is stabilizing into a moderate growth phase supported by its medical device and nutrition segments.
Abbott Laboratories is a diversified, mature global healthcare leader characterized by stable free cash flows and a reliable dividend profile (67% payout ratio). Following a volatile pandemic-era revenue trajectory, the company is stabilizing into a moderate growth phase supported by its medical device and nutrition segments.
Diversified portfolio across high-margin medical devices, diagnostics, and nutrition.
Entrenched global distribution networks and vast regulatory expertise.
Aging demographic tailwinds and normalized elective procedure volumes drive sustained, high-margin medical device demand.
Buy rating affirmed with a fair value of $107.02, driven by resilient intrinsic cash conversion and sustainable mature dividend distributions.
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
A macroeconomic shock would compress ABT's normalized 17% operating margins. Given the rigid 67% dividend payout ratio, resultant FCF drops would severely restrict capital flexibility for M&A and R&D, forcing increased balance sheet leverage.
Diversified portfolio across high-margin medical devices, diagnostics, and nutrition.
Entrenched global distribution networks and vast regulatory expertise.
Sticky recurring revenue from diabetes care (FreeStyle Libre).
Economic profit is supported when reported returns exceed the company cost-of-capital hurdle.
Unavailable
FCFF DCF remains positive at the base case: base FCFF $7.9B after capex $2.1B, with terminal value at 69.1% of enterprise value. No FCF cliff is projected unless capex/ or materially resets.
If top-line misses, strictly assess whether the drag is a transitory FX/diagnostics issue or structural med-device weakness. A medical device miss warrants immediate thesis re-evaluation.
If top-line misses, strictly assess whether the drag is a transitory FX/diagnostics issue or structural med-device weakness. A medical device miss warrants immediate thesis re-evaluation.
If top-line misses, strictly assess whether the drag is a transitory FX/diagnostics issue or structural med-device weakness. A medical device miss warrants immediate thesis re-evaluation.
If top-line misses, strictly assess whether the drag is a transitory FX/diagnostics issue or structural med-device weakness. A medical device miss warrants immediate thesis re-evaluation.
Mature phase emphasizing robust shareholder cash returns over aggressive greenfield capacity expansion.
Aging demographic tailwinds and normalized elective procedure volumes drive sustained, high-margin medical device demand.
Hospital budget constraints and global FX volatility suppress capital equipment and routine diagnostic spend.
Mature phase emphasizing robust shareholder cash returns over aggressive greenfield capacity expansion.
Core portfolio holding; limit to maximum 5% weighting given current accounting quality flags and low F-score.
Strong Buy.
Valuation synthesized primarily from a robust FCFF DCF ($128.91) anchored against near-term forward earnings estimates ($97.91). A strict DDM floor ($56.35) adequately penalizes the high 67% payout ratio restricting capital flexibility.
Buy.
Reassess the thesis against the named valuation, risk, and quarterly checkpoint evidence in this report.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Macroeconomic headwinds, persistent FX drag, and intense pricing pressure in Established Pharmaceuticals and Nutrition compress operating margins. Subpar accounting metrics foreshadow structural profitability deterioration, severely limiting dividend growth.
Next-gen competitive continuous glucose monitors or GLP-1 drug advancements severely erode FreeStyle Libre adoption, cratering high-margin medical device growth.
Persistent input cost inflation and generic competition fundamentally impair the pediatric and adult nutrition segments' operating leverage.
Sustained FCF deterioration due to aggressive pricing pressure forces a dividend cut, shattering the mature dividend payer archetype premium.
The five developments that would weaken our investment case.
Sustained margin contraction would indicate unabsorbed input cost inflation and pricing pressure across core medical devices and nutrition lines, impairing overall earnings conversion and restricting cash available for reinvestment in new product pipelines.
Current:18.2% for the period ended 2025-12-31
Alert if< 15.0% for two consecutive quarters
A drop in cash flow relative to reported net earnings would highlight aggressive working capital expansion or uncollected receivables, undermining reported earnings quality and reducing discretionary liquidity needed for ongoing operations.
Current:1.466 as of the report's 2026-05-09 analysis date
Alert if< 1.0x over any trailing twelve-month period
Decelerating franchise sales caused by competing continuous glucose sensor devices or adoption of GLP-1 therapies would compress medical device revenue expansion, eroding high-margin recurring consumables sales and dampening enterprise top-line momentum.
Current:5.7% total revenue growth for the period ended 2025-12-31
Alert if< 10.0% year-over-year over two consecutive quarters
Excessive dividend absorption of generated cash flow limits balance sheet flexibility for strategic acquisitions and research, creating severe financial strain and threatening the sustainability of ongoing shareholder distributions.
Current:67% as of the report's 2026-05-09 analysis date
Alert if> 85.0% of free cash flow for two consecutive quarters
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and at , then adjust for signed per current share.
Discount the explicit dividend path and its Gordon-growth terminal value at cost of equity.
Innovation in Medical Devices and sustained recovery in routine Diagnostics outpace expectations, yielding significant operating leverage. FCF conversion accelerates, enabling aggressive dividend hikes and synergistic acquisitions without compromising the balance sheet.
Following a volatile pandemic-era revenue trajectory, the company stabilizes into a moderate growth phase supported by its medical device and nutrition segments, reliably sustaining its 67% dividend payout ratio and robust intrinsic cash generation.
Warning level: < 15.0% for two consecutive quarters. Sustained margin contraction would indicate unabsorbed input cost inflation and pricing pressure across core medical devices and nutrition lines, impairing overall earnings conversion and restricting cash available for reinvestment in new product pipelines.
Warning level: < 1.0x over any trailing twelve-month period. A drop in cash flow relative to reported net earnings would highlight aggressive working capital expansion or uncollected receivables, undermining reported earnings quality and reducing discretionary liquidity needed for ongoing operations.
Warning level: < 10.0% year-over-year over two consecutive quarters. Decelerating franchise sales caused by competing continuous glucose sensor devices or adoption of GLP-1 therapies would compress medical device revenue expansion, eroding high-margin recurring consumables sales and dampening enterprise top-line momentum.
Warning level: > 85.0% of free cash flow for two consecutive quarters. Excessive dividend absorption of generated cash flow limits balance sheet flexibility for strategic acquisitions and research, creating severe financial strain and threatening the sustainability of ongoing shareholder distributions.
| $43.08B |
| $43.65B |
| $40.11B |
| $41.95B |
| $44.33B |
| +0.7% |
| Gross profit | $24.54B | $24.51B | $22.13B | $23.24B | $25.01B | +0.5% |
| Operating income | $8.74B | $8.86B | $7.30B | $7.57B | $8.96B | +0.6% |
| Net income | $7.07B | $6.93B | $5.72B | $13.40B | $6.52B | -2.0% |
| EPS (diluted) | — | $3.91 | $3.26 | $7.64 | $3.72 | -1.6% |
| EBITDA | $12.28B | $12.13B | $10.54B | $10.79B | $12.08B | -0.4% |
| R&D | $2.74B | $2.89B | $2.74B | $2.84B | $2.94B | +1.8% |
| SG&A | $11.32B | $11.25B | $10.95B | $11.70B | $12.33B | +2.2% |
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
| Revenue | 44,328,000,000 |
|---|---|
| Cost of revenue | 19,319,000,000 |
| Gross profit | 25,009,000,000 |
| Operating expenses | 16,956,000,000 |
| Operating income | 8,053,000,000 |
| Non-operating items and tax | -1,529,000,000 |
| Net income | 6,524,000,000 |
| Total assets | 86,713,000,000 |
|---|---|
| Cash | 8,522,000,000 |
| Current assets | 25,996,000,000 |
| Total liabilities | 33,942,000,000 |
| Current liabilities | 16,496,000,000 |
| Shareholders’ equity | 52,130,000,000 |
Point-in-time financial data used in the 2026-05-09 analysis.
| Period | Revenue | EBITDA | Net income | Operating cash flow | Free cash flow | Capex | Depreciation and amortization | Stock-based compensation | Share repurchases | Dividends paid | Net debt issuance | Investing cash flow | Financing cash flow | Beginning cash | Ending cash | Cash and investments | Total debt | Operating margin | ROIC | WACC | ROIC − WACC spread |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-12-31 | 43.1B | 12.3B | 7.1B | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 19.6% | — | 4.4% | — |
| 2022-12-31 | 43.7B | 12.1B | 6.9B | 9.6B | 7.8B | 1.8B | 3.3B | 685M | 3.8B | 3.3B | -699M | — | — | — | — | 9.9B | 17.7B | 19.2% | — | 6.8% | — |
| 2023-12-31 | 40.1B | 10.5B | 5.7B | 7.3B | 5.1B | 2.2B | 3.2B | 644M | 1.2B | 3.6B | -2.5B | — | — | — | — | 6.9B | 15.6B | 16.2% | — | 6.8% | — |
| 2024-12-31 | 42B | 10.8B | 13.4B | 8.6B | 6.4B | 2.2B | 3.2B | 673M | 1.3B | 3.8B | -537M | — | — | — | — | 7.6B | 15B | 16.3% | — | 7.4% | — |
| 2025-12-31 | 44.3B | 12.1B | 6.5B | 9.6B | 7.4B | 2.2B | 3.1B | 664M | 893M | 4.1B | -1.6B | — | — | — | — | 8.5B | 13.9B | 18.2% | — | 7.4% | — |
ABT trades at 13.9x forward earnings against a peer median of 14.3x; EV/EBITDA of 14.8x against a peer median of 16.4x; 6 peers.
| Level | Action |
|---|---|
| Thesis break |
| Medtronic plc |
| 12.6x |
| 2.8x |
| 12.5x |
| 9.4% |
| 20.0% |
| BSX | Boston Scientific Corporation | 14.3x | 3.9x | 16.4x | 14.7% | 20.6% |
| EW | Edwards Lifesciences Corporation | 23.8x | 7.3x | 22.6x | 10.4% | 31.2% |
| GEHC | GE HealthCare Technologies Inc. | 11.8x | 1.4x | 10.6x | 19.5% | 11.1% |
